News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
The specialty clinical research organization (CRO) focused on NASH, diabetes, obesity and related metabolic diseases, has named Brian Mooney to the role of chief operating officer (COO). Mooney replaces Dr. Linda Morrow, who has held the role since 2009 and will transition to chief medical officer.
Mooney was previously executive vice president, strategic service provision at Chiltern, a Covance company. In his new role as a member of the executive team, Mooney will lead operations for the company’s CRO and clinical research unit (CRU) divisions. He also will contribute to corporate strategy and senior client relationships.
“Over the last 15 years, ProSciento has cultivated the scientific expertise, scope of services, and operational expertise to be widely recognized as the leading CRO for early phase metabolic drug and device development, in particular, for NASH, diabetes and obesity. I’ve joined ProSciento to shape and accelerate the company’s global expansion of clinical operations and to further optimize efficiencies at its renowned early phase facility,” Mooney told us.
“ProSciento has a strong foothold in North America in terms of reputation and a network of clinical trial sites, and a growing footprint in Europe and Australia. With a keen focus on processes, efficiencies and quality, we look to broaden our access to specialty populations in the metabolic domain by further expanding capabilities in new and established regions, including Asia and Latin America.”